Journal of Diabetes & Metabolism

ISSN - 2155-6156


Efficacy on Tocotrienols in the Treatment of non-alcoholic Steatohepatitis: A 10 year Systematic Review

Higinio Mappala

Non-alcoholic fatty liver disease (NAFLD) is one of the most common forms of chronic liver disease which may progress to non-alcoholic steatohepatitis (NASH). Currently there are no therapeutic strategies for such disease. Only lifestyle modification through diet and exercise were proven to afford some benefit in patients with NAFLD. No pharmacologic agents have so far been approved for the treatment of NAFLD or NASH. Therefore, most clinical efforts have been directed at treating the components of metabolic syndrome, namely obesity, diabetes, hypertension and dyslipidemias.